Complement Components and Their Activation Products in Pleural Fluid: Statistical Methods

25 Jun
2014

Complement Components and Their Activation Products in Pleural Fluid: Statistical MethodsComparisons between groups with different etiology were performed with the Kruskal-Wallis and Mann-Whitney tests. Analyses of the predictors for the groups with different etiologies were studied using multinominal logistic regression analysis. Correlations between numeric variables were measured with Paerson’s correlation coefficient. The statistical computation was performed with software (STATISTICA; Statsoft Inc; Tulsa, OK, and a statistical program package BMDP; University of California Press; Berkeley, CA).
Results
The mean concentrations of plasma complement components and their activation products were within the normal range in all disease groups except that the patients with rheumatic pleural effusion had higher values of C4d and Cls-Clr-CIINH (Table 1) buy-asthma-inhalers-online.com buy proventil. In patients with rheumatoid arthritis, the mean concentrations of plasma Cls-Clr-CIINH and SC5b-9 were significantly higher than in patients with tuberculosis or malignancy (p <0.001).
In the pleural fluid, the mean values of complement components C3, C4, and factor B were lower and the mean levels of the activation products of complement components C3d, Bb, and SC5b-9 were higher than in plasma in all disease groups (Tables 1 and 2). The mean concentrations of C4d and Cls-Clr-CIINH in pleural fluid were within the same range in the different disease groups.
In rheumatic pleural effusions, the concentrations of C3 and C4 were low and the concentrations of SC5b-9, C3d, Bb, and the ratio C4d/C4 were high (Fig 1). There was a correlation between the levels of C3d and C4d (r=0.84) but not between the levels of C3d and Bb (r=0.49). The ratio of C4d/C4 was significantly higher than in tuberculous (p=0.03) or malignant pleural effusion (p—0.01).
In rheumatic pleural fluid, the mean concentration of SC5b-9 (29.3 AU/mL) was higher than in malignant pleural effusion (0.29 AU/mL) (p<0.001) (Fig 1). There was no patient with rheumatic pleurisy whose pleural fluid SC5b-9 level was lower than 2 AU/mL and all patients with malignant pleural fluid had SC5b-9 lower than 2 AU/mL. In addition, the mean concentrations of C3 and C4 were significantly lower (p=0.013, p<0.001, respectively) in rheumatic pleurisy compared with malignancy.

Table 1—The Components of Complements in Plasma

Tuberculosis(n=23)Rheumatic(n=10)Malignancy(n=38)ReferenceValues
C3, mg/mL Mean (SD) Median (Q1-Q3)0.98 (0.21)0.98 (0.86-1.11)0.99 (0.16)1.03 (0.85-1.08)1.09 (0.32)1.07 (0.98-1.16)0.55-1.20
C3d, U/mL Mean (SD) Median (Q1-Q3)5.87 (3.56)5.40 (3.80-9.00)6.04 (3.29)6.20 (3.60-9.10)4.17 (2.83)4.05 (2.60-5.85)<7
C4, mg/mL Mean (SD) Median (Q1-Q3)0.43 (0.19)0.36 (0.26-0.55)0.36 (0.05)0.36 (0.31-0.42)0.44 (0.99)0.42 (0.38-0.51)0.20-0.50
C4d, (jig/mL Mean (SD) Median (Q1-Q3)5.30    (2.34)5.30    (3.60-7.10)8.21 (4.87)6.70 (4.50-10.8)5.43 (3.45)5.00 (3.20-7.80)<7
FB, mg/mL Mean (SD) Median (Q1-Q3)0.29 (0.07)0.29 (0.24-0.34)0.29(0.10)0.30 (0.25-0.39)0.30 (0.07)0.30 (0.25-0.37)0.10-0.40
Bb, (ig/inl. Mean (SD) Median (Q1-Q3)0.93 (0.63)0.80 (0.53-1.35)1.51 (1.38)1.02 (0.50-2.60)1.20(1.01)0.99 (0.56-1.70)<4.0
Cls-Clr-CIINH, % Mean (SD)Median (Q1-Q3)1.97(1.04)* 2.21 (0.86-2.74)17.7 (21.0)8.87 (2.89-19.6)2.15(1.17)* 2.01 (1.07-3.03)<3.57
SC5b-9, AU/mL Mean (SD) Median (Q1-Q3)0.13 (0.09)* 0.10 (0.07-0.15)1.13(1.35)0.48 (0.40-0.85)0.13 (0.09)* 0.11 (0.05-0.19)<0.40

Table 2—The Components of Complements in Pleural Fluid

Tuberculosis(n=23)Rheumatic(n=10)Malignancy(n=38)
C3, mg/mL
Mean (SD)0.50 (0.23)*0.28 (0.13)0.44 (0.16)*
Median (Q1-Q3)0.53 (0.33-0.63)0.31 (0.25-0.36)0.42 (0.33-0.53)
C3d, U/mL
Mean (SD)24.7 (24.7)t18.3(16.7)8.28 (7.03)
Median (Q1-Q3)16.2 (6.80-33.0)12.9 (7.40-26.7)5.85 (2.80-13.8)
C4, mg/mL
Mean (SD)0.20 (0.14)}0.05 (0.03)0.14 (0.06)S
Median (Q1-Q3)0.17(0.07-0.30)0.06 (0.04-0.06)0.13 (0.09-0.18)
C4d, fjLg/mL
Mean (SD)6.52 (3.54)6.91 (4.62)5.46 (3.05)
Median (Q1-Q3)6.00 (4.00-9.70)6.20 (3.20-8.40)4.80 (3.60-8.20)
C4d/C4, X 0.001
Mean (SD)50.3 (46.8)*100.8 (54.8)47.3 (37.3)*
Median (Q1-Q3)32.1 (20.9-66.5)105.8 (46.7-131.7)37.3 (23.1-56.4)
FB, mg/mL
Mean (SD)0.15 (0.07)0.10 (0.05)0.15 (0.06)
Median (Q1-Q3)0.14(0.10-0.19)0.12(0.07-0.13)0.15 (0.10-0.20)
Bb, |Xg/mL
Mean (SD)8.30 (7.09)10.9 (9.76)3.99 (3.70)
Median (Q1-Q3)8.35 (2.00-11.5)7.45 (3.60-16.5)3.15(1.50-5.10)
Cls-Clr-CIINH, %
Mean (SD)2.03 (2.21)2.90 (2.69)1.54 (1.06)
Median (Q1-Q3)1.58 (0.87-2.49)2.40 (0.86-3.81)1.18 (0.74-2.28)
SC5b-9, AU/mL
Mean (SD)9.88 (28.5)51129.3 (39.4)0.29 (0.19)1
Median (Q1-Q3)0.78 (0.43-1.41)6.63 (2.60-37.2)0.25 (0.12-0.43)

Figure 1. The concentrations of complement components and their activation products in pleural fluid and plasma in patients with tuberculous (TB), rheumatic (RA), and malignant (M) pleural effusion. The line indicates the mean concentration.

Figure 1. The concentrations of complement components and their activation products in pleural fluid and plasma in patients with tuberculous (TB), rheumatic (RA), and malignant (M) pleural effusion. The line indicates the mean concentration.

top